Annexon (ANNX) Amortizatization of Intangibles (2021 - 2026)
Annexon (ANNX) posted quarterly Amortizatization of Intangibles of $632000.0 for Q1 2026, down 65.84% year-over-year from $1.8 million in Q1 2025, and up 49.06% quarter-over-quarter from $424000.0 in Q4 2025.
Powered by 
Analysis
Annexon (ANNX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Annexon's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $632000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 65.84% year-over-year to $632000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 71.47% YoY), while the FY2025 annual figure was $4.0 million, down 55.77% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $632000.0, up from $424000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $3.1 million in Q3 2024, with the low at -$380000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $632000.0 (2026), against an average of $951058.8.
- The sharpest annual moves came in 2022 and 2024: Amortizatization of Intangibles tumbled 111.11% in 2022, then soared 1062.31% in 2024.
- Annexon's Amortizatization of Intangibles stood at $417000.0 in 2022, then sank by 37.65% to $260000.0 in 2023, then jumped by 1062.31% to $3.0 million in 2024, then tumbled by 85.97% to $424000.0 in 2025, then surged by 49.06% to $632000.0 in 2026.
- Business Quant data shows ANNX's Amortizatization of Intangibles at $632000.0 in Q1 2026, $424000.0 in Q4 2025, and $475000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 678,000.00 |
| 10 | Annexon | 971.85 Mn | 971.85 Mn | - | 259,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 259,000.00 |
| Mar 31, 2026 | 632,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 475,000.00 |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 3.02 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 260,000.00 |
| Sep 30, 2023 | 595,000.00 |
| Jun 30, 2023 | 793,000.00 |
| Mar 31, 2023 | 902,000.00 |
| Dec 31, 2022 | 488,000.00 |
| Sep 30, 2022 | 1.32 Mn |
| Jun 30, 2022 | -221,000.00 |
| Mar 31, 2022 | -380,000.00 |
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | -1.44 Mn |